What is HC Wainwright's Forecast for HOWL Q1 Earnings?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Werewolf Therapeutics in a research note issued to investors on Friday, November 8th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.38) for the quarter. The consensus estimate for Werewolf Therapeutics' current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Werewolf Therapeutics' Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.42) EPS and Q4 2025 earnings at ($0.43) EPS.

Werewolf Therapeutics Trading Down 4.3 %

NASDAQ HOWL traded down $0.10 during trading on Monday, hitting $2.20. The stock had a trading volume of 768,861 shares, compared to its average volume of 374,011. The company has a market capitalization of $96.14 million, a PE ratio of -1.44 and a beta of 0.41. The company has a quick ratio of 12.13, a current ratio of 12.13 and a debt-to-equity ratio of 0.24. The firm has a 50 day moving average price of $2.27 and a 200 day moving average price of $2.96. Werewolf Therapeutics has a twelve month low of $1.66 and a twelve month high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $2.00 million. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 55.97%.

Hedge Funds Weigh In On Werewolf Therapeutics

Institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC purchased a new position in shares of Werewolf Therapeutics in the 1st quarter valued at about $10,922,000. Millennium Management LLC boosted its stake in shares of Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company's stock valued at $2,709,000 after buying an additional 544,881 shares during the period. Vanguard Group Inc. boosted its stake in shares of Werewolf Therapeutics by 26.8% in the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company's stock valued at $7,176,000 after buying an additional 233,909 shares during the period. Marshall Wace LLP boosted its stake in shares of Werewolf Therapeutics by 410.5% in the 2nd quarter. Marshall Wace LLP now owns 134,184 shares of the company's stock valued at $327,000 after buying an additional 107,900 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in shares of Werewolf Therapeutics by 119.8% in the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company's stock valued at $1,119,000 after buying an additional 94,212 shares during the period. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.